Hy-Tech Engineers is currently signalling the highest potential listing gain among the three IPOs at 56.6%, ahead of Symbiotec Pharmalab at 34.41% and Skyways Air at 23.19%, according to the latest grey market trends.
The three IPOs span pharmaceuticals, industrial engineering and air logistics, giving investors exposure to three distinct business segments.
Skyways Air vs Symbiotec Pharmalab vs Hy-Tech Engineers IPO GMP Compared
IPO GMP, upper price band, and estimated listing price are key factors in determining potential listing gain.
Skyways Air is fetching a grey market premium of Rs 32 as of 9:30 a.m. on August 25, with an estimated listing price of Rs 170 per share, indicating a potential listing gain of 23.19%.
Symbiotec Pharmalab is commanding a robust GMP of Rs 340 as of 9:30 a.m. on August 25, with an estimated listing price of Rs 1,328 per share, suggesting a solid listing gain of 34.41%.
Hy-Tech Engineers is leading the trio in subscription demand, with its issue subscribed 10.16 times by 10:30 a.m. on August 25.
IPO Details and Subscription Status
The Rs 582.80-crore Skyways Air IPO is a book-built issue, consisting of a fresh equity sale of Rs 398.80 crore alongside an offer-for-sale (OFS) of Rs 184 crore.
Related: Sunshine Pictures lists at 10 percent premium
Symbiotec Pharmalab has a book-built offering valued at Rs 1,757 crore, including a fresh issue of Rs 150 crore and an OFS of Rs 1,607 crore.
Hy-Tech Engineers is a Rs 135.73-crore mainboard IPO, comprising a fresh issue worth Rs 60 crore and an OFS valued at Rs 75.73 crore.
As the subscription window remains open, market participants are keeping a keen eye on demand metrics, overall market sentiment, and GMP movements to gauge potential debut performance.
Based on the latest GMP, Hy-Tech Engineers currently signals the highest potential listing gain in percentage terms, driven by a Rs 30 GMP over its Rs 53 upper band, implying a 56.6% listing gain.
The basis of allotment is slated to be finalised by August 28, paving the way for a likely debut on the BSE and NSE on September 1.
With the subscription window still open, investors are closely watching the demand metrics and GMP movements to gauge the potential debut performance of these IPOs.
